摘要
慢性肾脏疾病(CKD)是一种进行性疾病,其特点是肾脏功能永久和不可逆转的丧失。根据国际指南,CKD临床诊断方法根据肌酐和白蛋白水平以及肾小球滤过率。不幸的是,这些参数在早期阶段几乎不受影响,其固有的内在可变性只允许确定中间和高级阶段,即预期寿命缩短和治疗构成重大财政投资的阶段。在这方面,若干有针对性的战略aI‘我是为寻找新的标记而设计的。其中,以蛋白质组学和代谢组学研究为基础的“组学”技术应运而生。尿液和血清样本已被选定为起始样本。用于鉴定新的CKD生物标志物,能够区分分期和预测进展结果的材料。在许多情况下,主要目标是快速开发和可靠的无创分析的临床方法,在疾病的早期进展阶段。另一方面,在识别与C相关的分子方面,已经做出了重大的努力。KD的终末期,为了得到充分的治疗,减少损伤,并对生存率有积极的影响。本文介绍了新提出的CKD识别生物标志物的研究现状。综述了其分子多样性,强调了其化学结构差异,并与其生物学相关性进行了比较。在这方面的努力可以提供NCE代谢途径失衡,导致CKD评价和管理的新的整体策略的发展。
关键词: 慢性肾脏疾病(CKD),ESRD,生物标志物,肾小球滤过率,肌酐,代谢组学,蛋白质组学。
Current Medicinal Chemistry
Title:Chronic Kidney Disease and the Search for New Biomarkers for Early Diagnosis
Volume: 25 Issue: 31
关键词: 慢性肾脏疾病(CKD),ESRD,生物标志物,肾小球滤过率,肌酐,代谢组学,蛋白质组学。
摘要: Chronic kidney disease (CKD) is a progressive condition characterized by a permanent and irreversible loss of renal function. In accordance to international guidelines, CKD clinical diagnosis methods are based on creatinine and albumin levels and glomerular filtration rate. Unfortunately, these parameters are scarcely affected in early stages, and its inherent intrinsic variability only allows for the identification of intermediate and advanced stages, when life expectancy has become shorter and treatment poses a significant financial investment. In this context, several targeted strategies have been designed for searching novel markers. Among them, "omics" techniques have emerged, mainly based on proteomics and metabolomics research. Urine and serum samples have been selected as starting material to conduct the identification of new CKD biomarkers, capable of differentiating between stages and predicting progression outcomes. In many cases, the principal objective is to develop a fast and reliable clinical method for non-invasive analysis in the early progression stages of the disease. On the other hand, significant efforts have been directed to identify molecules related to the CKD end stage in order to adequate therapies, reduce impairments, and have a positive impact on survival rate. In this article, the state of the art of novel proposed biomarkers for CKD identification is reviewed, with the aim of underlining its molecular diversity, emphasizing chemical structure differences and correlating its biological relevance. Efforts directed in this line could provide evidence of metabolic pathways imbalance, and lead to the development of new integral strategies for CKD evaluation and management.
Export Options
About this article
Cite this article as:
Chronic Kidney Disease and the Search for New Biomarkers for Early Diagnosis, Current Medicinal Chemistry 2018; 25 (31) . https://dx.doi.org/10.2174/0929867325666180307110908
DOI https://dx.doi.org/10.2174/0929867325666180307110908 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Objectively Assessed Physical Activity and Sedentary Behaviour During Pregnancy in Portuguese Women: Differences Between Trimesters and Weekdays and Weekends
Current Women`s Health Reviews Cardiovascular Aspect of Beta-Thalassaemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Hypertension and Cardiac Arrhythmias
Current Pharmaceutical Design Brain Inflammation, Cholesterol, and Glutamate as Interconnected Participants in the Pathology of Alzheimers Disease
Current Pharmaceutical Design Targeting MCP-1 to Reduce Vascular Complications of Obesity
Recent Patents on Cardiovascular Drug Discovery Estrogen Receptor-α: Plasma Membrane Localization and Functions
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Endothelial Therapy of Atherosclerosis and its Risk Factors
Current Vascular Pharmacology The Coronary Artery Risk Detection in Appalachian Communities (CARDIAC) Project: An 18 Year Review
Current Pediatric Reviews Hydrogen Peroxide Produced by Mitochondrial Monoamine Oxidase Catalysis: Biological Implications
Current Pharmaceutical Design Research on the Pathological Mechanism and Drug Treatment Mechanism of Depression
Current Neuropharmacology Semi-Quantitative Ultrasonographic Evaluation of NAFLD
Current Pharmaceutical Design Model Systems for Pulmonary Infectious Diseases: Paradigms of Anthrax and Tuberculosis
Current Topics in Medicinal Chemistry Pathophysiology of Coronary Thrombus Formation and Adverse Consequences of Thrombus During PCI
Current Cardiology Reviews Mechanisms Involved in Metformin Action in the Treatment of Polycystic Ovary Syndrome
Current Pharmaceutical Design Long Term Complications in Pediatric Liver Transplant Recipients: What Every Pediatrician Should Know
Current Pediatric Reviews Assessing Myocardial Metabolism with Hybrid PET Imaging: Instrumentation, Concepts, and Workflows
Current Pharmaceutical Design Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design Overview of Therapeutic Potential of Rapamycin for Coronary Artery Diseases in the Era of the Drug-Eluting Stent
Vascular Disease Prevention (Discontinued) Telemonitoring in the Management of High Blood Pressure
Current Pharmaceutical Design New Patentable Use of an Old Neuroleptic Compound Thioridazine to Combat Tuberculosis: A Gene Regulation Perspective
Recent Patents on Anti-Infective Drug Discovery